Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Boehringer Ingelheim
Moodys
Baxter
Medtronic

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,534,218

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,534,218
Title:Expression of maize codon optimized proteins in pseudomonas fluorescens
Abstract: Compositions and methods for improving expression of a recombinant protein or polypeptide of interest in a host cell are provided. Compositions comprising a polynucleotide coding sequence for a BTBooster are provided using a plant optimized system. The coding sequences can be used in vector constructs or expression systems for transformation and expression of a recombinant protein or polypeptide of interest in a host cell. Methods comprising the codon optimization of a polynucleotide coding sequence for increased expression in a bacterial host are provided. The codon optimization method can be used in designing a polynucleotide coding sequence which expresses robust levels of protein in a bacterial host cell.
Inventor(s): Kelker; Matthew (Zionsville, IN), Woosley; Aaron T. (Fishers, IN)
Assignee: Dow AgroSciences LLC (Indianapolis, IN)
Application Number:14/409,416
Patent Claims:1. A method for codon optimizing a polynucleotide for the expression of a protein in a bacterial host cell, the method comprising replacing at least one codon in the polynucleotide with a codon that is used more frequently in the genes of a plant than in the genes of the bacterial host cell, such that GC and TA doublets are removed from the polynucleotide sequence; predicted ribonucleic acid (RNA) stem-loop-forming structures are removed from the polynucleotide sequence; at least one restriction enzyme binding sequence is removed from the polynucleotide sequence; sequence blocks that have more than about six consecutive residues of [G+C] or [A+T] are removed from the polynucleotide sequence; and exon:intron junctions, poly-A addition signals, and RNA polymerase termination signals are removed from the polynucleotide sequence.

2. A bacterial host cell comprising the polynucleotide produced by the method according to claim 1.

3. The bacterial host cell of claim 2, wherein the bacterial host cell is a Pseudomonas host cell, and Escherichia host cell, an Acidovorax host cell, and Brevundimonas host cell, an Burkholderia host cell, an Hydrogenophaga host cell, an Oceanimonas host cell, an Ralstonia host cell, an Stenotrophomonas host cell, an Sphingomonas host cell, an Xanthomonas host cell, or an Acidomonas host cell.

4. The method according to claim 1, wherein the at least one codon is replaced with a codon that is used more frequently in the genes of a monocotyledonous plant than in the genes of the bacterial host cell, or the at least one codon is replaced with a codon that is used more frequently in the genes of a dicotyledonous plant than in the genes of the bacterial host cell.

5. The method according to claim 1, wherein the at least one codon is replaced with a codon that is used more frequently in the genes of Zea mays than in the genes of the bacterial host cell.

6. The method according to claim 1, wherein the bacterial host cell is a Pseudomonas host cell, and Escherichia host cell, an Acidovorax host cell, and Brevundimonas host cell, an Burkholderia host cell, an Hydrogenophaga host cell, an Oceanimonas host cell, an Ralstonia host cell, an Stenotrophomonas host cell, an Sphingomonas host cell, an Xanthomonas host cell, or an Acidomonas host cell.

7. The method according to claim 1, wherein the bacterial host cell is a Pseudomonas fluorescens host cell.

8. The method according to claim 5, wherein the bacterial host cell is a Pseudomonas fluorescens host cell.

9. A method for codon optimizing a polynucleotide encoding a protein for the expression of the protein in a bacterial host cell, the method comprising replacing at least one codon in the polynucleotide with a codon that is used more frequently in the genes of a plant than in the genes of the bacterial host cell.

10. The method according to claim 9, wherein the at least one codon is replaced with a codon that is used more frequently in the genes of Zea mays than in the genes of the bacterial host cell.

11. The method according to claim 9, wherein the bacterial host cell is a Pseudomonas fluorescens host cell.

12. The method according to claim 10, wherein the bacterial host cell is a Pseudomonas fluorescens host cell.

Summary for Patent:   Start Trial

PCT Information
PCT FiledJune 13, 2013PCT Application Number:PCT/US2013/045548
PCT Publication Date:December 27, 2013PCT Publication Number:WO2013/191997

Details for Patent 9,534,218

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Dow AgroSciences LLC (Indianapolis, IN) 2032-06-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Dow AgroSciences LLC (Indianapolis, IN) 2032-06-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Dow AgroSciences LLC (Indianapolis, IN) 2032-06-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKesson
Harvard Business School
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.